Recent developments include clinical trial progress for GTB-3650 and GTB-5550, FDA IND clearances, leadership appointments, and financial updates.

• GT Biopharma recorded a Q1 loss of $2 million and advanced GTB-3650 in Phase 1 trial for leukemia [N1].
• The company dosed the first patient in the Phase 1 trial of GTB-5550 for solid tumors in May 2026 [N2].
• GT Biopharma announced FDA clearance of the IND application for GTB-5550 TriKE targeting B7-H3 solid tumors in February 2026 [N4].
• GT Biopharma submitted IND applications for GTB-5550 TriKE targeting B7-H3 solid tumors in January 2026 [N5, N6].
• David C. Mun-Gavin was appointed to the Board of Directors in June 2025 [N7].
• GT Biopharma advanced to Cohort 2 in Phase 1 trial of GTB-3650 following successful safety review of Cohort 1 in May 2025 [N8].

The company’s proprietary TriKE platforms offer a novel immuno-oncology approach that may provide safer and more effective cancer therapies by harnessing natural killer cells. Progression of GTB-3650 and GTB-5550 into clinical trials with FDA clearance and initial patient dosing demonstrates advancement in pipeline development. The scalable platform targeting multiple tumor antigens across hematologic malignancies, solid tumors, and autoimmune disorders could enable broad therapeutic applications. Collaborations with academic leaders and ongoing intellectual property generation support potential future commercialization opportunities.

GT Biopharma is a clinical-stage company with no approved products and no revenue, sustaining operating losses and using cash in operations. There is substantial doubt about its ability to continue as a going concern within one year due to ongoing losses and cash burn. Clinical development risks include potential failure to demonstrate safety and efficacy in trials, regulatory hurdles, and competition from other immuno-oncology therapies. Increased operating expenses and reliance on financing through equity and debt raise financial risks. Manufacturing and commercialization challenges for novel biologics also present execution risks.

GT Biopharma’s moat is based on its proprietary TriKE and Dual Targeting TriKE platforms that uniquely engage and activate natural killer cells to target cancer cells. The use of camelid nanobody technology in second-generation TriKEs enhances potency and specificity. Exclusive rights to the TriKE platform and ongoing intellectual property development provide barriers to entry. Collaborations with leading academic institutions and a pipeline targeting multiple tumor antigens across hematologic and solid tumors further support its competitive position. However, as a clinical-stage company without approved products, the moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: The company’s product candidates are in early clinical stages, and there is risk that they may not demonstrate safety or efficacy required for regulatory approval.
• Financial Risk: Sustained operating losses and cash burn raise substantial doubt about the company’s ability to continue as a going concern within one year, requiring additional financing.
• Regulatory Risk: The company’s therapies require FDA and other regulatory approvals, which involve complex and uncertain processes.
• Operational Risk: Increased operating expenses, including research and development and selling, general and administrative costs, may strain resources.
• Manufacturing and Commercialization Risk: Challenges in scaling production and commercializing novel biologics could impact future success.

• GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology products based on proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® fusion protein immune cell engager technology platforms [S1].
• The TriKE and Dual Targeting TriKE platforms harness and enhance the cancer-killing abilities of a patient's natural killer (NK) cells by activating them to target specific proteins on cancer or virus-infected cells, leading to targeted cell death [S1].
• TriKEs can be designed to target multiple tumor antigens including B7-H3, HER2, CD33, and PDL1 on hematologic malignancies or solid tumors without patient-specific customization [S1].
• The company believes its TriKE platforms may be safer than T-cell immunotherapy due to less cytokine release syndrome and fewer neurological complications, supported by preclinical data showing NK cell proliferation with minimal effect on T cells [S1].
• GT Biopharma's product pipeline includes GTB-3550 (first-generation TriKE targeting CD33, clinical development suspended), GTB-3650 (second-generation camelid nanobody TriKE targeting CD33 for AML and MDS, in Phase 1 clinical trials), GTB-5550 (B7-H3 targeted TriKE for solid tumors, FDA IND cleared and Phase 1 basket trial initiated), and GTB-7550 (TriKE in development for lupus and autoimmune disorders targeting CD19) [S1, S3, S4].
• GTB-3650 uses camelid nanobody technology for enhanced potency and is being tested in relapsed/refractory AML and high-risk MDS patients with dosing regimens designed to prevent NK cell exhaustion [S1, S3].
• GTB-5550 targets B7-H3 expressed on a broad spectrum of solid tumors including head and neck, prostate, breast, ovarian, glioblastoma, and lung cancers; FDA cleared IND in January 2026 with first patient dosed in May 2026 [S1, N4, N2].
• GTB-7550 is a tri-specific molecule targeting CD16 on NK cells and CD19 on malignant and normal B cells, with preclinical data showing activity against chronic lymphocytic leukemia; manufacturing partnerships are being explored [S3, S4].
• The company has exclusive rights to the TriKE platform and is generating additional intellectual property for specific moieties [S1].
• GT Biopharma has sustained operating losses since inception and has not generated revenue from product sales; net loss for the six months ended June 30, 2026 was approximately $7.35 million with operating cash outflow of about $6.7 million [S2].
• Operating expenses increased significantly in recent periods, driven by higher research and development costs related to materials and production, and increased selling, general and administrative expenses including marketing, legal, and consulting fees [S2].
• Liquidity as of June 30, 2026 included cash and equivalents of approximately $4.96 million, current assets of $5.79 million, current liabilities of $2.22 million, resulting in a current ratio of 2.61 and a cash ratio of 5.78 [S2].
• The company has financed operations through public and private sales of common and preferred stock, convertible debt, and strategic collaborations [S2].
• GT Biopharma's financial statements have been prepared assuming the company will continue as a going concern, but there is substantial doubt about its ability to continue as such within one year due to ongoing losses and cash usage [S2].
• The company entered into a clinical trial agreement with the University of Minnesota to sponsor an IND application and Phase 1a/1b clinical trial for GTB-5550, with a budget of approximately $3.8 million over three years [S22].
• Recent news highlights include dosing the first patient in the Phase 1 trial of GTB-5550 for solid tumors in May 2026, FDA clearance of the IND application for GTB-5550 in February 2026, and advancement of GTB-3650 into Phase 1 clinical trials with multiple cohorts enrolled [N2, N4, N1, N8].
• David C. Mun-Gavin was appointed to the Board of Directors in June 2025 [N7].